At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 270 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects With Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment With a Platinum Agent
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Various Advanced Cancer. Completed, enrolled 270 participants across 67 sites in 11 countries.
Detailed Summary
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVarious Advanced Cancer
CountriesAustralia, Belgium, Czechia, Finland, Germany, Italy, Japan, Poland, Spain, Sweden, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedMar 2015
Primary CompletionApr 2016
Study CompletionNov 2021
TodayJul 2026
First PostedMar 13, 2015
Enrollment StartMar 9, 2015
Primary CompletionApr 15, 2016
Study CompletionNov 12, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.3 years ago
Interventions
Nivolumabdrug